<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>24852726</identifier>
<setSpec>1578-2190</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Daudén Tello, E</dc:author>
<dc:author>Ribera Pibernat, M</dc:author>
<dc:author>Carrascosa Carrillo, J M</dc:author>
<dc:author>Puig Sanz, L</dc:author>
<dc:author>Belinchón Romero, I</dc:author>
<dc:author>Sánchez-Regaña, M</dc:author>
<dc:author>Ferrándiz Foraster, C</dc:author>
<dc:author>Aldunce Soto, M J</dc:author>
<dc:author>Herrera Acosta, E</dc:author>
<dc:author>Ruiz-Villaverde, R</dc:author>
<dc:author>Lafuente-Urrez, R F</dc:author>
<dc:author>Fonseca Capdevila, E</dc:author>
<dc:author>Marrón Moya, S E</dc:author>
<dc:author>Rodríguez Cerdeira, M C</dc:author>
<dc:author>Alsina Gibert, M M</dc:author>
<dc:author>Vidal Sarró, D</dc:author>
<dc:description xml:lang="en">Psoriatic lesions affecting the scalp, nails, palms, and the soles of the feet are described as difficult-to-treat psoriasis and require specific management. Involvement of these sites often has a significant physical and emotional impact on the patient and the lesions are difficult to control with topical treatments owing to inadequate penetration of active ingredients and the poor cosmetic characteristics of the vehicles used. Consequently, when difficult-to-treat sites are involved, psoriasis can be considered severe even though the lesions are not extensive. Scant information is available about the use of biologic therapy in this setting, and published data generally comes from clinical trials of patients who also had moderate to severe extensive lesions or from small case series and isolated case reports. In this article we review the quality of the scientific evidence for the 4 biologic agents currently available in Spain (infliximab, etanercept, adalimumab, and ustekinumab) and report level i evidence for the use of biologics to treat nail psoriasis (level of recommendation A) and a somewhat lower level of evidence in the case of scalp involvement and palmoplantar psoriasis.</dc:description>
<dc:type>Consensus Development Conference</dc:type>
<dc:language>es</dc:language>
<dc:subject>Palms</dc:subject>
<dc:subject>Psoriasis</dc:subject>
<dc:subject>Uñas</dc:subject>
<dc:subject>Nails</dc:subject>
<dc:subject>Plantas</dc:subject>
<dc:subject>Scalp</dc:subject>
<dc:subject>Biologic agents</dc:subject>
<dc:subject>Cuero cabelludo</dc:subject>
<dc:subject>Palmas</dc:subject>
<dc:subject>Soles</dc:subject>
<dc:subject>Biológicos</dc:subject>
<dc:date>2014 Dec </dc:date>
<dc:title xml:lang="en">Evidence-based guidelines of the spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles).</dc:title>
<dc:publisher>Actas dermo-sifiliograficas</dc:publisher>
</metadata>
</record>
</pubmed-document>
